Company: COPL-UN
Filing Date: 2025-04-23
Form Type: S-1/A
Source: 0001829126-25-002866
Chunk: 116

Company: Copley Acquisition Corp
Filing Date: 2025-04-23
Form: S-1/A
Chunk 116
---
 is likely to make a substantial profit on its investment in us in the event we consummate an initial business combination, even if the business combination causes the trading price of our ordinary shares to materially decline.

We are offering our units
at an offering price of $10.00 per unit and the amount in our trust account is initially anticipated to be $10.05 per public share, implying
an initial value of $10.05 per public share. However, prior to this offering, our sponsor paid a nominal aggregate purchase price of
$25,000 for the founder shares, or approximately $0.004 per share (assuming no exercise of the over-allotment option). Additionally,
if we increase or decrease the size of this offering, we will effect a share capitalization or a share repurchase or surrender or other
appropriate mechanism immediately prior to the consummation of this offering in such amount as to maintain the number of founder shares
at 25% of our issued and outstanding founder shares and public shares upon the consummation of this offering. Any additional founder
shares issued to our sponsor through such a share capitalization would be issued at their nominal par value. As a result of the nominal
aggregate purchase price paid by the sponsor for the founder shares, the value of your public shares may be significantly diluted upon
the consummation of our initial business combination, when the founder shares are converted into public shares. For example, the following
table shows the dilutive effect of the founder shares on the implied value of the public shares upon the consummation of our initial
business combination, assuming that our equity value at that time is $146,250,000 which is the amount we would have for our initial business
combination in the trust account after payment of $4,500,000 of deferred underwriting commissions, assuming the underwriters’ over-allotment
option is not exercised, no interest is earned on the funds held in the trust account, and no public shares are redeemed in connection
with our initial business combination, and without taking into account any other potential impacts on our valuation at such time, such
as the trading price of our public shares, the business combination transaction costs, any equity issued or cash paid to the target’s
sellers or other third parties, or the target’s business itself, including its assets, liabilities, management and prospects, as
well as the value of our public and placement warrants. At such valuation, each of our ordinary shares would have an implied value of